HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Smoking Rate 25% Annual Reduction Attainable - Surgeon General

This article was originally published in The Tan Sheet

Executive Summary

Combination treatments using nicotine replacement therapies and healthcare provider intervention could "produce cessation rates" of up to 25% per year, U.S. Surgeon General David Satcher, MD/PhD, concludes in a report released Aug. 9.

You may also be interested in...



Smoking Cessation Pregnancy Data Required For Alternative Warning Use

OTC nicotine-replacement therapy manufacturers who wish to use a pregnancy/breastfeeding warning different from new, FDA-revised labeling "will have to provide data to support alternative wording," the agency says.

Smoking Cessation Patch, Gum Prop 65 Warning Federally Preempted - Court

Requiring a special California Proposition 65 pregnancy warning on OTC nicotine-containing smoking cessation patches and gums would conflict with FDA requirements, a San Francisco state court judge has ruled.

Nicotine Replacement "Not First Choice" During Pregnancy - Duke's Slotkin

Doctors are recommending pregnant women use nicotine replacement therapies to stop smoking without fully considering their effect on the fetus, according to Theodore Slotkin, PhD, Duke University Medical Center. He spoke at a FDA seminar May 17 on the implications of smoking and nicotine replacement in pregnancy.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel